Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
News|Articles|April 14, 2025
Pharma Pulse 4/14/25: Four Ways to Increase Speed to Therapy, What Does the End of DEI Mean For SDOH efforts? & more
Author(s)Miranda Schmalfuhs
The latest news for pharma industry insiders.
Advertisement
The key strategies for reducing or eliminating post-prescription abandonment.
The end of federal diversity, equity and inclusion programs in the federal government may have a ripple effect on social determinants of health efforts.
Tariffs on pharmaceuticals would hurt patients and drugs should be exempt from these levies, AstraZeneca Plc’ Chairman Michel Demaré said.
The "Personalized Medicine Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The market is expected to reach US $1 trillion by 2033 from US $546.97 billion in 2024, with a CAGR of 7.05% from 2025 to 2033.
Hyfe's CEO Tamsin Chislett recently spoke to
We’re thrilled to be featured, and even more excited about what’s ahead.
👀 Curious? Catch the full story here:
Have news you want us to share in Pharma Pulse? Reach out to Editor
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5